NASDAQ:ISRG - Intuitive Surgical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $479.56 -3.11 (-0.64 %) (As of 11/20/2018 10:48 AM ET)Previous Close$482.67Today's Range$462.68 - $484.0652-Week Range$359.75 - $581.12Volume13,217 shsAverage Volume923,479 shsMarket Capitalization$59.22 billionP/E Ratio66.71Dividend YieldN/ABeta1.02 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. The company's da Vinci surgical System translates a surgeon's natural hand movements, which are performed on instrument controls at a console into corresponding micro-movements of instruments positioned inside the patient through small incisions or ports. Its da Vinci surgical system include surgeon's consoles, patient-side carts, 3-D vision systems, da Vinci skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures. The company also manufactures EndoWrist instruments that include forceps, scissors, electrocautery, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures. In addition, it offers da Vinci Single-Site instruments and accessories that allow surgical systems to work through a single incision; and EndoWrist One vessel sealers that are wristed single-use instruments intended for bipolar coagulation and mechanical transection of vessels up to 7 mm in diameter and tissue bundles that fit in the jaws of the instrument. Further, the company provides EndoWrist stapler, a wristed stapling instrument intended for resection, transection, and/or creation of anastomoses, as well as sells various accessories, including replacement 3-D stereo endoscopes, camera heads, light guides, and other items that facilitate use of the da Vinci system, as well as sterile drapes for ensuring a sterile field during surgery. Intuitive Surgical, Inc. markets its products directly and through distributors in the United States, Europe, Asia, and internationally. The company was founded in 1995 and is headquartered in Sunnyvale, California. Receive ISRG News and Ratings via Email Sign-up to receive the latest news and ratings for ISRG and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:ISRG Previous Symbol CUSIP46120E60 Webwww.intuitivesurgical.com Phone408-523-2100 Debt Debt-to-Equity RatioN/A Current Ratio6.05 Quick Ratio5.52 Price-To-Earnings Trailing P/E Ratio66.71 Forward P/E Ratio50.37 P/E Growth3.48 Sales & Book Value Annual Sales$3.13 billion Price / Sales17.50 Cash Flow$7.9044 per share Price / Cash60.67 Book Value$42.19 per share Price / Book11.37 Profitability EPS (Most Recent Fiscal Year)$7.19 Net Income$660 million Net Margins22.31% Return on Equity18.79% Return on Assets15.97% Miscellaneous Employees4,444 Outstanding Shares114,200,000Market Cap$59.22 billion OptionableOptionable Intuitive Surgical (NASDAQ:ISRG) Frequently Asked Questions What is Intuitive Surgical's stock symbol? Intuitive Surgical trades on the NASDAQ under the ticker symbol "ISRG." When did Intuitive Surgical's stock split? How did Intuitive Surgical's stock split work? Intuitive Surgical's stock split on Friday, October 6th 2017. The 3-1 split was announced on Friday, August 11th 2017. The newly minted shares were issued to shareholders after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Intuitive Surgical stock prior to the split would have 300 shares after the split. How were Intuitive Surgical's earnings last quarter? Intuitive Surgical, Inc. (NASDAQ:ISRG) released its quarterly earnings data on Thursday, October, 18th. The medical equipment provider reported $2.83 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $2.66 by $0.17. The medical equipment provider had revenue of $920.90 million for the quarter, compared to analysts' expectations of $916.22 million. Intuitive Surgical had a net margin of 22.31% and a return on equity of 18.79%. The company's revenue for the quarter was up 14.0% on a year-over-year basis. During the same quarter last year, the business posted $2.77 earnings per share. View Intuitive Surgical's Earnings History. When is Intuitive Surgical's next earnings date? Intuitive Surgical is scheduled to release their next quarterly earnings announcement on Thursday, January 24th 2019. View Earnings Estimates for Intuitive Surgical. What price target have analysts set for ISRG? 18 equities research analysts have issued 12-month target prices for Intuitive Surgical's shares. Their predictions range from $300.00 to $635.00. On average, they expect Intuitive Surgical's stock price to reach $558.9412 in the next year. This suggests a possible upside of 16.4% from the stock's current price. View Analyst Price Targets for Intuitive Surgical. What is the consensus analysts' recommendation for Intuitive Surgical? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intuitive Surgical in the last year. There are currently 1 sell rating, 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intuitive Surgical. What are Wall Street analysts saying about Intuitive Surgical stock? Here are some recent quotes from research analysts about Intuitive Surgical stock: 1. According to Zacks Investment Research, "Intuitive Surgical outperformed the industry in a year’s time. The company’s robotic platform – da Vinci procedures –recorded solid growth in recent times. Higher worldwide da Vinci procedures led by growth in U.S. general surgery procedures and global urologic procedures is a positive. A regulatory approval for the Sure Form 60 buoys optimism. Earlier this year, the company submitted a premarket notification to the FDA for the Ion endoluminal system. Management is also optimistic about the company’s collaboration with InTouch Health. On the flipside, the company expects outside U.S. sales to be a bit lumpy in the quarters ahead. These markets are in early stages of adoption. Intense competition in niche space as well as long sale and purchase order cycles of da Vinci unit has been currently plaguing the company." (11/15/2018) 2. BTIG Research analysts commented, "Procedures Accelerate Intuitive reported another strong quarter but this time procedures accelerated to ~20% y/y growth. On the procedure side, hernia continues to be the strongest growth contributor with management noting hernia is no longer in the first innings but has plenty of growth potential to come. Colorectal continued strong US growth while core GYN and prostate trends remained healthy in the US. OUS prostate growth paced Europe while Japan saw ~40% growth driven by newly established reimbursement. Systems again topped the Street but this includes a larger contribution from leases. We believe getting systems out in the field makes sense, but at the high valuation, some investors may not want to give full credit for leases that do not drive full ASPs up front." (10/21/2018) 3. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating on shares of ISRG and maintain our price target of $620. ISRG momentum continued as the company significantly beat all the metrics we track. ISRG delivered 20% procedure growth for 3Q18, the highest quarterly procedure growth since 2012. ISRG again raised full-year 2018 procedure growth guidance to 17-18% from 14.5-16.5%. The global installed based grew 13% and utilization was up by mid-single digits. The strong quarterly growth and expanding number of future growth drivers continue to justify ISRG’s premium valuation, in our view." (10/19/2018) 4. Northland Securities analysts commented, "We continue to be DEAD WRONG on the stock. The argument on this stock is now primarily about how much you can stretch valuation. The stock currently trades at ~ 15x forward P/S and ~54x forward P/E. We are not sure in what world these metrics can be sustained. The confluence of 4 factors….a nutty market which has no correlation to fundamentals, lack of any serious competition from the likes of MDT and JNJ, positive f/x contribution due to the weaker dollar, and finally, a lower tax rate due to the recent tax law passed, are yielding higher returns." (7/20/2018) Has Intuitive Surgical been receiving favorable news coverage? News stories about ISRG stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Intuitive Surgical earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned news headlines about the medical equipment provider a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. Who are some of Intuitive Surgical's key competitors? Some companies that are related to Intuitive Surgical include Edwards Lifesciences (EW), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Align Technology (ALGN), Smith & Nephew (SNN), Steris (STE), WILLIAM DEMANT/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Inogen (INGN), Avanos Medical (AVNS), Establishment Labs (ESTA), Sientra (SIEN), RTI Surgical (RTIX) and Invacare (IVC). Who are Intuitive Surgical's key executives? Intuitive Surgical's management team includes the folowing people: Dr. Gary S. Guthart, CEO, Pres & Director (Age 52)Mr. Marshall L. Mohr, Sr. VP & CFO (Age 62)Mr. Salvatore J. Brogna, Exec. VP & COO (Age 63)Mr. David J. Rosa, Exec. VP & Chief Commercial Officer (Age 50)Dr. Myriam J. Curet McAdams, Exec. VP & Chief Medical Officer (Age 61) Who are Intuitive Surgical's major shareholders? Intuitive Surgical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.79%), FMR LLC (5.78%), Bank of New York Mellon Corp (2.60%), Capital World Investors (2.58%), Edgewood Management LLC (2.19%) and Baillie Gifford & Co. (2.01%). Company insiders that own Intuitive Surgical stock include Alan J Levy, Amal M Johnson, Colin Morales, Craig H Barratt, Curet Myriam, David J Rosa, Gary S Guthart, Jamie Samath, Keith R Leonard, Lonnie M Smith, Mark J Meltzer, Mark J Rubash, Marshall Mohr, Michael A Friedman and Salvatore Brogna. View Institutional Ownership Trends for Intuitive Surgical. Which institutional investors are selling Intuitive Surgical stock? ISRG stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, American Century Companies Inc., MERIAN GLOBAL INVESTORS UK Ltd, Alliancebernstein L.P., Mitsubishi UFJ Trust & Banking Corp, Janus Henderson Group PLC, Cornerstone Wealth Management LLC and Point72 Asset Management L.P.. Company insiders that have sold Intuitive Surgical company stock in the last year include Amal M Johnson, Craig H Barratt, Curet Myriam, David J Rosa, Gary S Guthart, Jamie Samath, Lonnie M Smith, Mark J Meltzer, Mark J Rubash, Marshall Mohr, Michael A Friedman and Salvatore Brogna. View Insider Buying and Selling for Intuitive Surgical. Which institutional investors are buying Intuitive Surgical stock? ISRG stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Mirae Asset Global Investments Co. Ltd., Capital World Investors, BlackRock Inc., AQR Capital Management LLC, KAMES CAPITAL plc, Edgewood Management LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Intuitive Surgical. How do I buy shares of Intuitive Surgical? Shares of ISRG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Intuitive Surgical's stock price today? One share of ISRG stock can currently be purchased for approximately $480.25. How big of a company is Intuitive Surgical? Intuitive Surgical has a market capitalization of $59.22 billion and generates $3.13 billion in revenue each year. The medical equipment provider earns $660 million in net income (profit) each year or $7.19 on an earnings per share basis. Intuitive Surgical employs 4,444 workers across the globe. What is Intuitive Surgical's official website? The official website for Intuitive Surgical is http://www.intuitivesurgical.com. How can I contact Intuitive Surgical? Intuitive Surgical's mailing address is 1020 KIFER ROAD, SUNNYVALE CA, 94086. The medical equipment provider can be reached via phone at 408-523-2100 or via email at [email protected] MarketBeat Community Rating for Intuitive Surgical (NASDAQ ISRG)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 759 (Vote Outperform)Underperform Votes: 526 (Vote Underperform)Total Votes: 1,285MarketBeat's community ratings are surveys of what our community members think about Intuitive Surgical and other stocks. Vote "Outperform" if you believe ISRG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISRG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/20/2018 by MarketBeat.com StaffFeatured Article: What does cost of debt say about a company’s financial health?